Corpus Intelligence IC Memo — RUSSELL MEDICAL CENTER 2026-04-26 03:43 UTC
IC Memo — RUSSELL MEDICAL CENTER
Investment Committee Memorandum | AL | 45 beds | Grade C | EBITDA uplift $5.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RUSSELL MEDICAL CENTER

CCN 010065 | TALLAPOOSA, AL | 45 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

RUSSELL MEDICAL CENTER is a 45-bed under-performing / distressed in TALLAPOOSA, AL with $75.3M in net patient revenue and a -14.8% operating margin. The hospital serves a payer mix of 31.9% Medicare, 16.5% Medicaid, and 51.6% commercial.

Thesis: Turnaround. Our ML models identify $5.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -14.8% to -7.4% (+736bps).

Net Revenue HCRIS$75.3M
Current EBITDA COMPUTED$-11.1M
Operating Margin COMPUTED-14.8%
Occupancy HCRIS46.4%
Revenue / Bed COMPUTED$1.7M
Net-to-Gross HCRIS30.6%
Distress Probability ML51.4%

2. Market Context & Competitive Position

115
AL Hospitals
-8.5%
State Median Margin
58
Comparable Hospitals

AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -14.8% places it below the state median. Among 58 size-comparable peers (22-90 beds), the median margin is -16.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (22-90), prioritizing same-state peers. 58 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RUSSELL MEDICAL CENTER (Target)AL45$75.3M-14.8%
ATHENS LIMESTONEAL66$88.9M-20.9%
JACK HUGHSTON MEMORIAL HOSPITAAL47$75.2M6.5%
EASTPOINTE HOSPITALAL66$56.6M-50.0%
NORTH BALDWIN INFIRMARYAL35$55.3M-3.3%
PRATTVILLE BAPTIST HOSPITALAL55$53.5M-16.2%
HIGHLANDS MEDICAL CENTERAL45$45.9M-30.2%
ENCOMPASS HEALTH REHABILITATIOAL85$42.1M17.9%
ST. VINCENTS ST. CLAIRAL40$40.8M8.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.6M+210bp18mo
Cost to Collect4.5%2.5%$1.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$916K+122bp9mo
Clean Claim Rate88.0%96.0%$48K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.6M
Cost to Collect
$1.5M
Denial Rate Reduction
$1.5M
A/R Days Reduction
$916K
Clean Claim Rate
$48K
Total EBITDA Uplift$5.5M
Current EBITDA$-11.1M
+ RCM Uplift+$5.5M
Pro Forma EBITDA$-5.6M
Current Margin-14.8%
Pro Forma Margin-7.4%
WC Released (1x)$2.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-17.1M$-18.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-17.1M$-25.4M0.00x-100.0%
Bull Case9.0x11.0x$-15.4M$-12.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-15.4M$-18.4M0.00x-100.0%
Bear Case11.0x10.0x$-18.8M$-40.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-18.8M$-50.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 51.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 58 hospitals with 22-90 beds
  • Same-state prioritization (n=59)
  • Comp margins: P25=-26.6% / P50=-16.0% / P75=1.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.